Should You Buy Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) or Individual Pot Stocks?

Buying the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) has many advantages over buying single pot stocks.

| More on:
edit Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) is the world’s first marijuana ETF. It seeks to replicate the performance of the North American Marijuana Index, net of expenses. This index gives exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry.

Issuers have in general a market capitalization higher than $75 million. The three largest holdings are Aurora Cannabis, Canopy Growth, and Cronos Group.

HMMJ’s performance since its inception on April 5, 2017, is 21%. However, stocks in the cannabis sector have been sinking quite a lot recently. As a result, HMMJ has dropped 26% in the last three months only.

If you’re looking to invest in the marijuana sector, you may wonder if you should invest in HMMJ or buy individual pot stocks. I’ll tell you the reasons why you should buy HMMJ and also give you the downsides of buying the ETF versus owning individual stocks, so you can make an informed choice.

Why you should buy HMMJ

If you’re not familiar with the marijuana industry or don’t want to take big risks with your money, then I believe HMMJ is a good choice to make your entry in the pot sector.

While HMMJ is very volatile and carries a high risk, it is less risky than buying a stock, because the ETF is very diversified. Concentration risk is limited, as no issuer represents more than 10% of the index on each re-balance date.

A good example of this is CannTrust (TSX:TRST)(NYSE:CTST). This stock has dropped 84% from its peak, erasing all gains since its IPO two years ago. The pot company has lost nearly two-thirds of its value since early July when it revealed it had violated Canadian regulations by cultivating cannabis in unlicensed areas of its greenhouse in Pelham, Ontario, potentially putting its licence at risk.

People that invested in shares of CannTrust have thus lost a lot of money. However, this stock represents less than 0.5% of HMMJ, so its effect on the ETF’s value is mitigated. So, by buying HMMJ instead of a single pot stock, you have less risk of losing all your money.

Further, it would require a big amount of money to buy the 10 largest marijuana stocks, but with the EFT, you get exposure to many issuers with little money invested.

In addition, HMMJ is very liquid, meaning you can buy or sell it easily. The average monthly daily trading volume is generally greater than 75,000 shares a day, with a trading value generally higher than $250,000. Some small pot stocks have low liquidity and thus, you could have trouble trading them at the current market price.

What are the downsides?

The main downside of owning a marijuana ETF is, like with any other ETF, that you give up the upside potential of owning an individual stock. That is, while there are pot stocks that perform less well than HMMJ, such as CannTrust, there are other pot stocks that may perform better than the ETF.

For instance, Fire & Flower Holdings, a small pot company with a market cap of $150 million, has soared 5% in the last three months, performing much better than HMMJ. But Fire & Flower is more volatile than HMMJ, meaning you could lose more money if things turn bad.

If you still want to buy single cannabis stocks to profit from a bigger upside potential, you should limit the money you invest in those. Don’t put all your money into one pot stock, and don’t forget to also diversify outside the marijuana sector to lower your risk.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf owns shares of Aurora Cannabis, Cronos Group, and Horizons Medical Marijuana Life Sci ETF.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »